Roche: partnership with Cend in pancreatic cancer
(CercleFinance.com) - On Wednesday Caladrius and Cend announced that Cend has entered into a collaboration agreement with Roche to develop a new treatment for pancreatic cancer.
Under the terms of the partnership, both companies will initiate a Phase 1b/2 clinical trial to evaluate the efficacy of the combination of Cend-1, Cend's lead drug candidate, and Tecentriq, Roche's immunotherapy, in patients with metastatic pancreatic ductal adenocarcinoma.
The agreement calls for Roche to take over the operational management of the trial, while Cend and Roche will equally share the costs associated with providing therapeutic doses of Cend-1.
Caladrius and Cend recently announced that they will merge to form Lisata Therapeutics, a deal that is expected to close by the end of September.
Copyright (c) 2022 CercleFinance.com. All rights reserved.